Theranexus announced the initial results of their Phase I/II clinical trial for juvenile Batten disease (CLN3). After a 9-week course of Batten-1 with the maximum dose of 600 mg/day, the first results of the Phase I/II trial enrolling six patients with juvenile Batten disease (CLN3) aged 17 and over showed good patient safety and tolerability, and a pharmacokinetic profile in line with expectations.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.12 EUR | +0.45% | +1.82% | 0.00% |
04-29 | Theranexus Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
04-19 | Theranexus: share price rises following promising trial results | CF |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
0.00% | 9.36M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- ALTHX Stock
- News Theranexus
- Theranexus Announces the Initial Results of Their Phase I/II Clinical Trial for Juvenile Batten Disease